The role of intraarticular injections of hyaluronic acid in joint pain relief in hemophilic arthropathy
Expert Rev Hematol. 2023 Oct 14:1-7. doi: 10.1080/17474086.2023.2271660. Online ahead of print.ABSTRACTINTRODUCTION: Chronic pain in hemophilic patients is due to joint degeneration associated with hemophilic arthropathy. In addition to appropriate hematological treatment (primary prophylaxis), pharmacologic management and Physical Medicine and Rehabilitation should be indicated. When such measures are not sufficient, intraarticular injections (IAIs) of hyaluronic acid (HyA) may be considered.AREAS COVERED: In order to determine whether IAIs of HyA are effective in terms of pain relief in individuals with painful moderate ...
Source: Expert Review of Hematology - October 14, 2023 Category: Hematology Authors: E Carlos Rodriguez-Merchan Source Type: research

The role of intraarticular injections of hyaluronic acid in joint pain relief in hemophilic arthropathy
Expert Rev Hematol. 2023 Oct 14. doi: 10.1080/17474086.2023.2271660. Online ahead of print.ABSTRACTINTRODUCTION: Chronic knee pain in hemophilic patients is due to joint degeneration associated with hemophilic arthropathy. In addition to appropriate hematological treatment (primary prophylaxis), pharmacologic management and physical medicine and rehabilitation (PMR) should be indicated. When such measures are not sufficient, intraarticular injections (IAIs) of hyaluronic acid (HyA) may be considered.AREAS COVERED: In order to determine whether IAIs of HyA are effective in terms of pain relief in individuals with painful mo...
Source: Expert Review of Hematology - October 14, 2023 Category: Hematology Authors: E Carlos Rodriguez-Merchan Source Type: research

Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy
Expert Rev Hematol. 2023 Oct 13. doi: 10.1080/17474086.2023.2271170. Online ahead of print.NO ABSTRACTPMID:37830359 | DOI:10.1080/17474086.2023.2271170 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - October 13, 2023 Category: Hematology Authors: Stefano Molica Source Type: research

Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
Expert Rev Hematol. 2023 Oct 11. doi: 10.1080/17474086.2023.2268273. Online ahead of print.ABSTRACTINTRODUCTION: Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are generally characterized by a poor prognosis with currently available therapies. Immunotherapies have already seen success in treating a variety of malignant disorders, and their role in managing myeloid cancers is evolving rapidly.AREAS COVERED: This is a review of the immunotherapies tested in MDS and AML, including immune checkpoint inhibitors, bispecific antibodies and cell therapies such as chimeric antigen receptor (CAR) T cell therapy, T c...
Source: Expert Review of Hematology - October 11, 2023 Category: Hematology Authors: David R Spillane Sarit Assouline Source Type: research

Quality of life considerations and management in patients with myelodysplastic syndrome
This study aimed to identify the factors affecting the quality of life (QOL) and functional status of patients with MDS.AREAS COVERED: We reviewed the literature published in PUBMED over the past 30 years and searched for keywords such as "quality of life" and "myelodysplastic syndromes". By observing the influence of their symptoms, the possibility of improving patients' QOL was considered by improving these related factors. Concurrently, the effects of related clinical treatments based on the unique disease characteristics of MDS on the patients' QOL were examined, and lifestyle factors were considered in clinical practi...
Source: Expert Review of Hematology - October 11, 2023 Category: Hematology Authors: Zhaoyun Liu Xintong Xu Kai Ding Rong Fu Source Type: research

Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
Expert Rev Hematol. 2023 Oct 11. doi: 10.1080/17474086.2023.2268273. Online ahead of print.ABSTRACTINTRODUCTION: Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are generally characterized by a poor prognosis with currently available therapies. Immunotherapies have already seen success in treating a variety of malignant disorders, and their role in managing myeloid cancers is evolving rapidly.AREAS COVERED: This is a review of the immunotherapies tested in MDS and AML, including immune checkpoint inhibitors, bispecific antibodies and cell therapies such as chimeric antigen receptor (CAR) T cell therapy, T c...
Source: Expert Review of Hematology - October 11, 2023 Category: Hematology Authors: David R Spillane Sarit Assouline Source Type: research

Quality of life considerations and management in patients with myelodysplastic syndrome
This study aimed to identify the factors affecting the quality of life (QOL) and functional status of patients with MDS.AREAS COVERED: We reviewed the literature published in PUBMED over the past 30 years and searched for keywords such as "quality of life" and "myelodysplastic syndromes". By observing the influence of their symptoms, the possibility of improving patients' QOL was considered by improving these related factors. Concurrently, the effects of related clinical treatments based on the unique disease characteristics of MDS on the patients' QOL were examined, and lifestyle factors were considered in clinical practi...
Source: Expert Review of Hematology - October 11, 2023 Category: Hematology Authors: Zhaoyun Liu Xintong Xu Kai Ding Rong Fu Source Type: research